Combination Drug Therapy

Results from a phase 2 clinical trial showed that treatment with an IgG-cleaving enzyme for individuals diagnosed with Guillain-Barré syndrome led to faster muscle strength recovery and mobility.

When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlights unmet needs in myeloproliferate neoplasms care and management.

Paolo Tarantino, MD, discusses the role of collaborative management of patients with metastatic breast cancer.

DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.

The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.

Healio spoke with Akriti Jain, MD, about the future of MDS research, specifically combination treatments like azacitidine and venetoclax.

The FDA has cleared an investigational new drug application for AlloNK in combination with rituximab to treat systemic lupus erythematosus in patients with active lupus nephritis, according to a press release from Artiva Biotherapeutics.